STERIS (STE) 10-Q 8 Aug 22 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Entity Information [Line Items]
Document Transition Report	false
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Entity Incorporation, State or Country Code	L2
Document Quarterly Report	true
Entity Registrant Name	STERIS plc
Local Phone Number	1 232 2000
Entity Central Index Key	0001757898
Document Type	10-Q
Entity File Number	001-38848
Document Period End Date	Jun. 30, 2022
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		100,014,639
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Tax Identification Number	98-1455064
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, State or Province	IE
Entity Address, Postal Zip Code	D02 R296
Trading Symbol	STE
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	353
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 316,327	$ 348,320
Accounts receivable (net of allowances of $23,121 and $24,371, respectively)	763,788	799,041
Inventories, net	620,404	574,999
Prepaid expenses and other current assets	147,428	156,637
Total current assets	1,847,947	1,878,997
Property, plant, and equipment, net	1,573,337	1,552,576
Operating Lease, Right-of-Use Asset	182,357	188,480
Goodwill	4,321,176	4,404,343
Intangible Assets, Net (Excluding Goodwill)	3,193,032	3,328,537
Other assets	70,157	70,661
Total assets	11,188,006	11,423,594
Current liabilities:
Accounts payable	228,987	225,737
Accrued income taxes	37,553	26,873
Accrued payroll and other related liabilities	137,580	183,721
Capital Lease Obligations, Current	35,560	36,472
Short-term Debt	151,000	142,875
Accrued expenses and other	317,643	306,544
Total current liabilities	908,323	922,222
Long-term indebtedness	2,846,446	2,945,481
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	790,819	780,619
Capital Lease Obligations, Noncurrent	150,215	155,056
Other Liabilities, Noncurrent	73,075	75,579
Total liabilities	4,768,878	4,878,957
Commitments and contingencies (see Note 8)
Common shares, with $.001 par value; 500,000 shares authorized; 100,090 and 100,067 shares issued and outstanding	4,738,746	4,742,920
Retained earnings	2,057,175	1,999,244
Accumulated other comprehensive income	(388,373)	(209,808)
Total shareholders' equity	6,407,548	6,532,356
Noncontrolling interest	11,580	12,281
Total equity	6,419,128	6,544,637
Total liabilities and equity	$ 11,188,006	$ 11,423,594

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Accounts Receivable, Allowance for Credit Loss, Current	$ 23,121	$ 24,371
Preferred Stock, Shares Authorized	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	$ 500,000	$ 500,000
Common Stock, Shares, Issued	500,000,000	500,000,000
Common Stock, Shares, Outstanding	100,090,000	100,067,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Intangible Assets, Net (Excluding Goodwill)	$ 3,193,032	$ 3,328,537

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 1,156,491	$ 968,422
Cost of revenues:
Cost of Goods and Services Sold	638,693	542,140
Gross Profit	517,798	426,282
Operating expenses:
Selling, general, and administrative	334,626	393,752
Research and development	24,751	18,192
Restructuring Costs	26	14
Total operating expenses	359,403	411,958
Income from operations	158,395	14,324
Non-operating expenses, net:
Interest expense	22,674	21,812
Fair value adjustment related to convertible debt liability	0	22,923
Interest income and miscellaneous expense	770	(1,434)
Total non-operating expenses, net	23,444	43,301
Income before income tax expense	134,951	(28,977)
Income tax expense	24,196	(7,075)
Net Income	110,755	(21,902)
Less: Net Income Attributable to Noncontrolling Interest	(507)	(95)
Net income (loss) attributable to shareholders	$ 111,262	$ (21,807)
Net income per common share [Abstract]
Basic	$ 1.11	$ (0.24)
Diluted	1.10	(0.24)
Cash dividends declared per common share outstanding	$ 0.43	$ 0.40
Product [Member]
Revenues:
Total revenues	$ 637,076	$ 489,279
Cost of revenues:
Cost of Goods and Services Sold	332,855	271,406
Service [Member]
Revenues:
Total revenues	519,415	479,143
Cost of revenues:
Cost of Goods and Services Sold	$ 305,838	$ 270,734

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Net Income	$ 110,755	$ (21,902)
Less: Net Income Attributable to Noncontrolling Interest	(507)	(95)
Net income (loss) attributable to shareholders	111,262	(21,807)
Other comprehensive (loss) income
Amortization of pension and postretirement benefits plans costs, (net of taxes of $(6) and $174, respectively)	29	(507)
Change in cumulative foreign current translation adjustment	(178,594)	24,933
Total other comprehensive (loss) income	(178,565)	24,426
Comprehensive income	$ (67,303)	$ 2,619

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Amortization of pension and postretirement benefits plans costs, tax	$ (6)	$ 174

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Net Income	$ 110,755	$ (21,902)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization	138,863	83,621
Deferred income taxes	5,304	456
Share-based compensation	8,963	26,600
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net	(972)	824
Fair value adjustment related to convertible debt liability	0	22,923
(Gain) loss on Disposition of Business	3,878	419
Other items	10,412	(2,334)
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net	26,335	41,732
Inventories, net	(58,076)	(1,660)
Other current assets	6,755	(6,747)
Accounts payable	6,492	(4,614)
Accruals and other, net	(26,963)	(41,892)
Net cash provided by operating activities	231,746	97,426
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(115,933)	(56,396)
Proceeds from the sale of property, plant, equipment, and intangibles	1,288	217
Proceeds from Divestiture of Businesses, Net of Cash Divested	5,228	0
Acquisition of businesses, net of cash acquired	0	(547,353)
Net cash used in investing activities	(109,417)	(603,532)
Financing activities:
Proceeds from Issuance of Senior Long-term Debt	0	1,350,000
Proceeds from Loans	0	650,000
Payments for Loans	(111,875)	(125,000)
Proceeds from (Repayments of) Other Long-term Debt	0	(721,284)
Proceeds (Payments) under credit facilities, net	37,011	(249,421)
Deferred financing fees and debt issuance costs	0	(17,227)
Acquisition related deferred or contingent consideration	(84)	(25,150)
Repurchases of ordinary shares	(24,679)	(10,670)
Cash dividends paid to ordinary shareholders	(43,008)	(34,148)
Stock option and other equity transactions, net	1,221	1,710
Net cash used in financing activities	(141,414)	818,810
Effect of exchange rate changes on cash and cash equivalents	(12,908)	1,539
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(31,993)	314,243
Cash and cash equivalents at beginning of period	348,320
Cash and cash equivalents at end of period	316,327
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 316,327	$ 534,774

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Shares, Issued					85,353
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,891,468	$ 10,478	$ (61,243)	$ 1,939,408	$ 2,002,825
Common Stock, Dividends, Per Share, Cash Paid	$ 0.40
Net Income (Loss) Attributable to Parent	$ (21,807)			(21,807)
Net Income (Loss) Attributable to Noncontrolling Interest	(95)	(95)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(21,902)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	24,426		24,426
Treasury Stock, Shares, Acquired					(60)
Payments for Repurchase of Common Stock	(10,670)			(8,894)	$ (1,776)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture					156
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	28,299				$ 28,299
Dividends, Common Stock, Cash	(34,148)			(34,148)
Stock Issued During Period, Value, Acquisitions	2,689,317				$ 2,689,317
Stock Issued During Period, Shares, Acquisitions					14,297
Consideration related to equity component of Cantel Convertible Debt	175,555				$ 175,555
Consideration Related to Cantel Equity Compensation Programs	18,173				18,173
Increase (Decrease) In Noncontrolling Interests, Other	52	52
Reclassification to Cantel convertible debt, premium liability	(175,555)				$ (175,555)
Shares, Issued					99,746
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,585,015
Stockholders' Equity Attributable to Parent			(36,817)	1,874,559	$ 4,736,838
Stockholders' Equity Attributable to Noncontrolling Interest		10,435
Shares, Issued					100,067
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,544,637	12,281	(209,808)	1,999,244	$ 4,742,920
Stockholders' Equity Attributable to Parent	6,532,356
Stockholders' Equity Attributable to Noncontrolling Interest	$ 12,281
Common Stock, Dividends, Per Share, Cash Paid	$ 0.43
Net Income (Loss) Attributable to Parent	$ 111,262			111,262
Net Income (Loss) Attributable to Noncontrolling Interest	(507)	(507)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	110,755
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(178,565)		(178,565)
Treasury Stock, Shares, Acquired					(126)
Payments for Repurchase of Common Stock	(24,679)			(10,323)	$ (14,356)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture					149
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	10,182				$ 10,182
Dividends, Common Stock, Cash	(43,008)			(43,008)
Increase (Decrease) In Noncontrolling Interests, Other	(194)	(194)
Shares, Issued					100,090
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,419,128
Stockholders' Equity Attributable to Parent	6,407,548		$ (388,373)	$ 2,057,175	$ 4,738,746
Stockholders' Equity Attributable to Noncontrolling Interest	$ 11,580	$ 11,580

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies(Notes)	3 Months Ended
	Jun. 30, 2022
Notes To Financial Statements [Abstract]
Nature of Operations	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal (“GI”) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integrati on. We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. We describe our business segments in Note 9 titled, "Business Segment Information." Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. The Consolidated Balance Sheet at March 31, 2022 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023. Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2022, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2023, $57,528 of the March 31, 2022 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2022, $35,722 of the March 31, 2021 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With reg ard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2022, the transaction price allocated to remaining performance obligations was approximately $1,574,000. We expect to recognize approximately 62% of the transaction price within one year and approximately 31% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have been adopted in fiscal 2023 ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. October 2021 The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. First Quarter Fiscal 2023 We adopted this standard effective April 1, 2022 with no material impact to our consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2022.

Business Acquisitions and Dives

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)	3 Months Ended
	Jun. 30, 2022
Business Acquisition, Date of Acquisition [Abstract]
Business Combination Disclosure	Business Acquisitions and Divestitures Acquisitions On June 2, 2021, we acquired all outstanding equity interests in Cantel Medical LLC ("Cantel") through a U.S. subsidiary. The total consideration for Cantel common stock and s tock equivalents was $3,599,471. We funded the cash portion of the transaction consideration and repayment of a significant amount of Cantel’s existing debt obligations with a portion of the proceeds from new debt, which is described in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. In addition to the total purchase consideration, STERIS assumed and repaid $721,284 of existing Cantel debt obligations and assumed Cantel's obligations associated with convertible senior notes issued on May 15, 2020, which is described our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. Fair Value of Assets Acquired and Liabilities Assumed The table below presents the allocation of fair values of assets acquired and liabilities assumed on the acquisition date. March 31, 2022 (As previously reported) Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant and equipment 267,360 (1,282) 266,078 Lease right-of-use assets, net 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471 Fiscal 2023 and 2022 first quarter acquisition and integration expenses totaled $9,832 and $140,996, respectively and were primarily related to the acquisition and integration of Cantel. Acquisition and integration expenses are reported in the selling, general and administrative expenses line of our Consolidated Statements of Income and include but are not limited to investment banker, advisory, legal, other professional fees, and certain employee-related expenses. For more information on the acquisition of Cantel, refer to our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022.

Inventories, Net (Notes)

Inventories, Net (Notes)	3 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 211,453 $ 195,035 Work in process 107,267 76,021 Finished goods 341,109 334,880 Reserve for excess and obsolete inventory (39,425) (30,937) Inventories, net $ 620,404 $ 574,999

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	3 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 82,795 $ 84,015 Buildings and leasehold improvements 651,071 654,851 Machinery and equipment 899,970 903,649 Information systems 223,455 222,620 Radioisotope 603,761 597,641 Construction in progress (1) 402,795 356,013 Total property, plant, and equipment 2,863,847 2,818,789 Less: accumulated depreciation and depletion (1,290,510) (1,266,213) Property, plant, and equipment, net $ 1,573,337 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	3 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Indebtedness was as follows: June 30, March 31, Short-term debt Term Loan, current portion $ 27,500 $ 27,500 Delayed Draw Term Loan, current portion 32,500 24,375 Private Placement Senior Notes 91,000 91,000 Total short-term debt $ 151,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 745,032 $ 758,726 Revolving Credit Facility 92,642 58,908 Deferred financing costs (24,353) (25,278) Term Loan 65,625 177,500 Delayed Draw Term Loan 617,500 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 2,846,446 $ 2,945,481 Total debt $ 2,997,446 $ 3,088,356 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022.

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	3 Months Ended
	Jun. 30, 2022
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 83,416 $ 71,878 Accrued vacation/paid time off 14,108 13,669 Accrued bonuses 23,174 64,702 Accrued employee commissions 13,598 30,171 Other postretirement benefit obligations-current portion 1,190 1,190 Other employee benefit plans obligations-current portion 2,094 2,111 Total accrued payroll and other related liabilities $ 137,580 $ 183,721 Accrued expenses and other: Deferred revenues $ 100,617 $ 110,791 Service liabilities 47,737 51,365 Self-insured risk reserves-current portion 11,421 8,995 Accrued dealer commissions 34,450 31,700 Accrued warranty 13,443 14,108 Asset retirement obligation-current portion 517 1,181 Accrued interest 18,073 10,014 Other 91,385 78,390 Total accrued expenses and other $ 317,643 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 19,213 $ 19,213 Other postretirement benefit obligations-long-term portion 7,070 7,335 Defined benefit pension plans obligations-long-term portion 3,601 1,772 Other employee benefit plans obligations-long-term portion 1,183 1,360 Accrued long-term income taxes 12,502 12,225 Asset retirement obligation-long-term portion 11,897 12,362 Other 17,609 21,312 Total other liabilities $ 73,075 $ 75,579

Income Tax Expense (Notes)

Income Tax Expense (Notes)	3 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Tax Expense	Income Tax Expense The effective income tax rates for the three-month periods ended June 30, 2022 and 2021 were 17.9% and 24.4%, respectively. The fiscal 2023 effective tax rate decreased when compared to fiscal 2022, primarily due to nonrecurring unfavorable items reported in the prior fiscal year. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous t axing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. With the exception of formal acceptance of the settlement noted below, we are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2016. We remain subject to tax authority audits in various jurisdictions wherever we do business. In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 through 2017. An agreement was reached on final interest rates, which also impacts subsequent years through 2020. We estimate the total federal, state, and local tax impact of the settlement to be approximately $12,000, for the fiscal years 2016 through 2020, of which approximately $7,500 has been paid through June 30, 2022. In May 2021, we received two notices of proposed tax adjustment from the IRS regarding deemed div idend inclusions and associated withholding tax. The notices relate to the fiscal and calendar year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50,000. We are contesting the IRS’s assertions, and intend to pursue available remedies such as appeals and litigation, if necessary. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

Contingencies (Notes)

Contingencies (Notes)	3 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and "- Environmental Matters", and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.

Business Segment Information (N

Business Segment Information (Notes)	3 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We report our financial information in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include single-use devices and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our Applied Sterilization Technologies ("AST") segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment. Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems. We d isclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated C ompany. Certain prior period costs were reallocated from the Healthcare segment to corporate to conform with current year presentation. The prior period segment operating income measure has been recast for comparability. For the three months e nded June 30, 2022, revenues from a single Customer did not represent ten percent or more of the Healthcare, Applied Sterilization Technologies or Life Sciences segment revenues. Three Customers collectively and consistently account for approximately 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for appr oxi mately 38.6% and 35.8% o f our Dental segment revenues for the three months ended June 30, 2022 and 2021, respectively. A dditional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. Financial information for each of our segments is presented in the following table: Three Months Ended June 30, 2022 2021 Revenues: Healthcare $ 698,526 $ 602,817 Applied Sterilization Technologies 220,911 208,902 Life Sciences 132,207 121,471 Dental 104,847 35,232 Total revenues $ 1,156,491 $ 968,422 Segment operating income (loss): Healthcare $ 156,497 $ 138,373 Applied Sterilization Technologies 109,315 101,927 Life Sciences 55,305 49,088 Dental 19,596 10,119 Corporate (75,943) (77,273) Total segment operating income $ 264,770 $ 222,234 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,929 $ 41,741 Acquisition and integration related charges (2) 9,832 140,996 Tax restructuring costs (3) 173 (49) (Gain) on fair value adjustment of acquisition related contingent consideration (1) (3,100) — Net loss on divestiture of businesses (1) 3,878 419 Amortization of inventory and property "step up" to fair value (1) 1,637 24,789 Restructuring charges (4) 26 14 Total income from operations $ 158,395 $ 14,324 (1) For more information regarding our recent acquisitions and divestitures refer to note 2 titled, "Business Acquisitions and Divestitures" of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts refer to our Annual R eport on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022. Additional information regarding our fiscal 2023 and fiscal 2022 first quarter revenue is disclosed in the following tables: Three Months Ended June 30, 2022 2021 Healthcare: Consumables $ 252,032 $ 206,692 Capital equipment 179,134 150,890 Service 267,360 245,235 Total Healthcare Revenues $ 698,526 $ 602,817 Total Applied Sterilization Technologies Revenues $ 220,911 $ 208,902 Life Sciences: Consumables $ 59,557 $ 56,536 Capital equipment 40,499 32,745 Service 32,151 32,190 Total Life Sciences Revenues $ 132,207 $ 121,471 Dental Revenues $ 104,847 $ 35,232 Total Revenues $ 1,156,491 $ 968,422 Additional geographic information regarding our revenues and property, plant and equipment, net is presented in the following tables: Three Months Ended June 30, 2022 2021 Revenues: Ireland $ 18,176 $ 21,945 United States 834,101 679,250 Other locations 304,214 267,227 Total Revenues $ 1,156,491 $ 968,422

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, Denominator (shares in thousands): 2022 2021 Weighted average shares outstanding—basic 100,082 90,152 Dilutive effect of share equivalents 640 840 Weighted average shares outstanding and share equivalents—diluted 100,722 90,992 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, (shares in thousands) 2022 2021 Number of share options 291 273 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Repurchases of Shares (Notes)

Repurchases of Shares (Notes)	3 Months Ended
	Jun. 30, 2022
Notes To Financial Statements [Abstract]
Repurchases of shares	Repurchases of Ordinary Shares On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of June 30, 2022, there was approximately $294,649 (net of taxes, fees and commissions) of remaining availability under a Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations. During the first three months of fiscal 2023, we repurchased 68,177 of our ordinary shares for the aggregate amount of $14,283 (net of fees and commissions) pursuant to the authorizations.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	3 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the option plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of June 30, 2022, 2,812,252 ordinary shares remained available for grant under the long-term incentive plan. The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first three months of fiscal 2023 and 2022: Fiscal 2023 Fiscal 2022 Risk-free interest rate 2.41 % 1.16 % Expected life of options 5.8 years 5.8 years Expected dividend yield of stock 0.80 % 0.97 % Expected volatility of stock 24.45 % 24.41 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.54% and 2.85% was applied in fiscal 2023 and 2022, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 222,384 250.06 Exercised (20,640) 53.20 Forfeited (6,326) 200.62 Outstanding at June 30, 2022 1,756,372 $ 153.29 6.9 years $ 105,081 Exercisable at June 30, 2022 1,109,471 $ 118.70 5.8 years $ 97,397 We estimate that 624,686 of the non-vested stock options outstanding at June 30, 2022 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $206.15 closing price of our ordinary shares on June 30, 2022 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first three months of fiscal 2023 and fiscal 2022 was $3,897 and $5,469, respectively. Net cash proceeds from the exercise of stock options were $1,221 and $1,710 for the first three months of fiscal 2023 and fiscal 2022, respectively. The weighted average grant date fair value of stock option grants was $50.04 and $36.24 for the first three months of fiscal 2023 and fiscal 2022, respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. As of May 24, 2021, we no longer have outstanding SARS. A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 119,588 5,824 227.46 Vested (137,898) (6,218) 121.81 Forfeited (6,167) (766) 164.04 Non-vested at June 30, 2022 461,033 32,517 $ 155.01 Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first three months of fiscal 2023 was $17,570. As of June 30, 2022, there was a total of $88,105 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.4 years. Cantel Share Based Compensation Plan In connection with the acquisition of Cantel, outstanding, non-vested Cantel restricted share units were replaced with STERIS restricted share units. A total of 280,402 STERIS restricted share units replaced Cantel awards based on a ratio of one Cantel restricted share unit to 0.4262 STERIS restricted share units. Cantel time based restricted share units were replaced with STERIS restricted share units with the same three-year pro-rata vesting terms based on the original award date. Performance based Cantel restricted share units were replaced with time based STERIS restricted share units that vest pro rata over the remaining one, two or three anniversaries from the original Cantel award date. The number of Cantel performance restricted share units was replaced based on the original target achievement level. All replacement restricted share units retained dividend accumulation rights. The fair value of each STERIS restricted share unit awarded on June 2, 2021 to replace outstanding non-vested Cantel restricted share units was $191.18 based on the closing price of STERIS ordinary shares on June 2, 2021. Approximately $18,173 of the total $53,607 grant date fair value was attributable to pre-acquisition services provided and was recorded as a component of purchase consideration in connection with the acquisition of Cantel. Recognition of unamortized share-based compensation expense totaling $197 and $18,545, for the first quarter of fiscal 2023 and 2022, respectively was accelerated in connection with the planned termination of certain Cantel executive level employees in fiscal 2023 . As a result of the formal notices provided and the terms of the Cantel share based compensati on plans and Cantel Executive Severance and Change of Control Plan, the remaining service required under the awards became non-substantive requiri ng acceleration of the remaining related compensation cost. As of June 30, 2022, there was a total of $4,438 in unrecognized compensation cost related to non-vested STERIS restricted share units awarded to replace Cantel restricted share units. We expect to recognize the cost over a weighted average of 1.0 year. A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below: Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 45,722 $ 191.18 Vested (2,578) 191.18 Forfeited (1,318) 191.18 Non-vested at June 30, 2022 41,826 $ 191.18

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	3 Months Ended
	Jun. 30, 2022
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first three months of fiscal 2023 were as follows: Warranties Balance, March 31, 2022 $ 14,108 Warranties issued during the period 3,285 Settlements made during the period (3,950) Balance, June 30, 2022 $ 13,443
Legal Matters and Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and "- Environmental Matters", and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.

Derivatives and Hedging (Notes)

Derivatives and Hedging (Notes)	3 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the first quarter of fiscal 2023, we also entered into forward foreign currency contracts in order to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2023. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At June 30, 2022, we held foreign currency forward contracts to sell 34.9 million euros. At June 30, 2022 we held commodity swap contracts to buy 601.2 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location June 30, 2022 March 31, 2022 June 30, 2022 March 31, 2022 Prepaid & Other $ 1,330 $ 2,780 $ — $ — Accrued expenses and other $ — $ — $ 783 $ 198 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended June 30, 2022 2021 Foreign currency forward contracts Selling, general and administrative $ 2,349 $ 1,428 Commodity swap contracts Cost of revenues $ (2,824) $ 664

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	3 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at June 30, 2022 and March 31, 2022: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 June 30, March 31, June 30, March 31, June 30, March 31, June 30, March 31, Assets: Cash and cash equivalents $ 316,327 $ 348,320 $ 316,327 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 1,330 2,780 — — 1,330 2,780 — — Equity investments (2) 7,178 8,520 7,178 8,520 — — — — Other investments 2,140 2,272 2,140 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 783 $ 198 $ — $ — $ 783 $ 198 $ — $ — Deferred compensation plans (2) 1,036 1,240 1,036 1,240 — — — — Total debt (3) 2,997,446 3,088,356 — — 2,725,916 2,991,680 — — Contingent consideration obligations (4) 7,518 10,550 — — — 7,518 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2023 and 2022, we recorded a (losses) of $(936) and $(16), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2022 are summarized as follows: Contingent Consideration Balance at March 31, 2022 $ 10,550 Adjustments (3,100) Additions 106 Payments (21) Currency translation adjustments (17) Balance at June 30, 2022 $ 7,518

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Jun. 30, 2022
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2022 and 2021 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2022 $ 1,276 $ (211,084) $ (209,808) Other Comprehensive (Loss) Income before reclassifications 154 (178,594) (178,440) Amounts reclassified from Accumulated Other Comprehensive (Loss) Income (125) — (125) Net current-period Other Comprehensive (Loss) Income 29 (178,594) (178,565) Balance at June 30, 2022 $ 1,305 $ (389,678) $ (388,373) (1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2021 $ (5,519) $ (55,724) $ (61,243) Other Comprehensive Income (Loss) before reclassifications 591 24,933 25,524 Amounts reclassified from Accumulated Other Comprehensive (Loss) (1,098) — (1,098) Net current-period Other Comprehensive (Loss) (507) 24,933 24,426 Balance at June 30, 2021 $ (6,026) $ (30,791) $ (36,817) (1) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2022 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2023.
Recently Issued Accounting Standards Impacting the Company	Recently Issued Accounting Standards Impacting the Company are presented in the following table:
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2022, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2023, $57,528 of the March 31, 2022 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2022, $35,722 of the March 31, 2021 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)	3 Months Ended
	Jun. 30, 2022
Business Acquisition, Date of Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	March 31, 2022 (As previously reported) Adjustments Final Cash $ 169,073 $ — $ 169,073 Accounts receivable 172,226 — 172,226 Inventory 249,221 — 249,221 Property, plant and equipment 267,360 (1,282) 266,078 Lease right-of-use assets, net 59,720 — 59,720 Other assets 72,864 — 72,864 Intangible assets 2,942,000 — 2,942,000 Goodwill 1,522,381 22,088 1,544,469 Total assets acquired 5,454,845 20,806 5,475,651 Convertible debt, par value 168,000 — 168,000 Other current liabilities 247,549 5,595 253,144 Long-term lease obligations 47,856 — 47,856 Deferred income taxes, net 670,685 15,211 685,896 Long-term indebtedness 721,284 — 721,284 Total liabilities assumed 1,855,374 20,806 1,876,180 Net assets acquired $ 3,599,471 $ — $ 3,599,471

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	3 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 211,453 $ 195,035 Work in process 107,267 76,021 Finished goods 341,109 334,880 Reserve for excess and obsolete inventory (39,425) (30,937) Inventories, net $ 620,404 $ 574,999

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	3 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 82,795 $ 84,015 Buildings and leasehold improvements 651,071 654,851 Machinery and equipment 899,970 903,649 Information systems 223,455 222,620 Radioisotope 603,761 597,641 Construction in progress (1) 402,795 356,013 Total property, plant, and equipment 2,863,847 2,818,789 Less: accumulated depreciation and depletion (1,290,510) (1,266,213) Property, plant, and equipment, net $ 1,573,337 $ 1,552,576 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	3 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: June 30, March 31, Short-term debt Term Loan, current portion $ 27,500 $ 27,500 Delayed Draw Term Loan, current portion 32,500 24,375 Private Placement Senior Notes 91,000 91,000 Total short-term debt $ 151,000 $ 142,875 Long-term debt Private Placement Senior Notes $ 745,032 $ 758,726 Revolving Credit Facility 92,642 58,908 Deferred financing costs (24,353) (25,278) Term Loan 65,625 177,500 Delayed Draw Term Loan 617,500 625,625 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 2,846,446 $ 2,945,481 Total debt $ 2,997,446 $ 3,088,356

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	3 Months Ended
	Jun. 30, 2022
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 83,416 $ 71,878 Accrued vacation/paid time off 14,108 13,669 Accrued bonuses 23,174 64,702 Accrued employee commissions 13,598 30,171 Other postretirement benefit obligations-current portion 1,190 1,190 Other employee benefit plans obligations-current portion 2,094 2,111 Total accrued payroll and other related liabilities $ 137,580 $ 183,721 Accrued expenses and other: Deferred revenues $ 100,617 $ 110,791 Service liabilities 47,737 51,365 Self-insured risk reserves-current portion 11,421 8,995 Accrued dealer commissions 34,450 31,700 Accrued warranty 13,443 14,108 Asset retirement obligation-current portion 517 1,181 Accrued interest 18,073 10,014 Other 91,385 78,390 Total accrued expenses and other $ 317,643 $ 306,544 Other liabilities: Self-insured risk reserves-long-term portion $ 19,213 $ 19,213 Other postretirement benefit obligations-long-term portion 7,070 7,335 Defined benefit pension plans obligations-long-term portion 3,601 1,772 Other employee benefit plans obligations-long-term portion 1,183 1,360 Accrued long-term income taxes 12,502 12,225 Asset retirement obligation-long-term portion 11,897 12,362 Other 17,609 21,312 Total other liabilities $ 73,075 $ 75,579

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	3 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following table: Three Months Ended June 30, 2022 2021 Revenues: Healthcare $ 698,526 $ 602,817 Applied Sterilization Technologies 220,911 208,902 Life Sciences 132,207 121,471 Dental 104,847 35,232 Total revenues $ 1,156,491 $ 968,422 Segment operating income (loss): Healthcare $ 156,497 $ 138,373 Applied Sterilization Technologies 109,315 101,927 Life Sciences 55,305 49,088 Dental 19,596 10,119 Corporate (75,943) (77,273) Total segment operating income $ 264,770 $ 222,234 Less: Adjustments Amortization of acquired intangible assets (1) $ 93,929 $ 41,741 Acquisition and integration related charges (2) 9,832 140,996 Tax restructuring costs (3) 173 (49) (Gain) on fair value adjustment of acquisition related contingent consideration (1) (3,100) — Net loss on divestiture of businesses (1) 3,878 419 Amortization of inventory and property "step up" to fair value (1) 1,637 24,789 Restructuring charges (4) 26 14 Total income from operations $ 158,395 $ 14,324
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended June 30, 2022 2021 Healthcare: Consumables $ 252,032 $ 206,692 Capital equipment 179,134 150,890 Service 267,360 245,235 Total Healthcare Revenues $ 698,526 $ 602,817 Total Applied Sterilization Technologies Revenues $ 220,911 $ 208,902 Life Sciences: Consumables $ 59,557 $ 56,536 Capital equipment 40,499 32,745 Service 32,151 32,190 Total Life Sciences Revenues $ 132,207 $ 121,471 Dental Revenues $ 104,847 $ 35,232 Total Revenues $ 1,156,491 $ 968,422
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended June 30, 2022 2021 Revenues: Ireland $ 18,176 $ 21,945 United States 834,101 679,250 Other locations 304,214 267,227 Total Revenues $ 1,156,491 $ 968,422

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, Denominator (shares in thousands): 2022 2021 Weighted average shares outstanding—basic 100,082 90,152 Dilutive effect of share equivalents 640 840 Weighted average shares outstanding and share equivalents—diluted 100,722 90,992
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, (shares in thousands) 2022 2021 Number of share options 291 273

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first three months of fiscal 2023 and 2022: Fiscal 2023 Fiscal 2022 Risk-free interest rate 2.41 % 1.16 % Expected life of options 5.8 years 5.8 years Expected dividend yield of stock 0.80 % 0.97 % Expected volatility of stock 24.45 % 24.41 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2022 1,560,954 $ 138.37 Granted 222,384 250.06 Exercised (20,640) 53.20 Forfeited (6,326) 200.62 Outstanding at June 30, 2022 1,756,372 $ 153.29 6.9 years $ 105,081 Exercisable at June 30, 2022 1,109,471 $ 118.70 5.8 years $ 97,397
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 485,510 33,677 $ 157.37 Granted 119,588 5,824 227.46 Vested (137,898) (6,218) 121.81 Forfeited (6,167) (766) 164.04 Non-vested at June 30, 2022 461,033 32,517 $ 155.01
Share-based Payment Arrangement, Activity	Number of Restricted Share Units Weighted-Average Non-vested at March 31, 2022 45,722 $ 191.18 Vested (2,578) 191.18 Forfeited (1,318) 191.18 Non-vested at June 30, 2022 41,826 $ 191.18

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	3 Months Ended
	Jun. 30, 2022
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first three months of fiscal 2023 were as follows: Warranties Balance, March 31, 2022 $ 14,108 Warranties issued during the period 3,285 Settlements made during the period (3,950) Balance, June 30, 2022 $ 13,443

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	3 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location June 30, 2022 March 31, 2022 June 30, 2022 March 31, 2022 Prepaid & Other $ 1,330 $ 2,780 $ — $ — Accrued expenses and other $ — $ — $ 783 $ 198
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended June 30, 2022 2021 Foreign currency forward contracts Selling, general and administrative $ 2,349 $ 1,428 Commodity swap contracts Cost of revenues $ (2,824) $ 664

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at June 30, 2022 and March 31, 2022: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 June 30, March 31, June 30, March 31, June 30, March 31, June 30, March 31, Assets: Cash and cash equivalents $ 316,327 $ 348,320 $ 316,327 $ 348,320 $ — $ — $ — $ — Forward and swap contracts (1) 1,330 2,780 — — 1,330 2,780 — — Equity investments (2) 7,178 8,520 7,178 8,520 — — — — Other investments 2,140 2,272 2,140 2,272 — — — — Liabilities: Forward and swap contracts (1) $ 783 $ 198 $ — $ — $ 783 $ 198 $ — $ — Deferred compensation plans (2) 1,036 1,240 1,036 1,240 — — — — Total debt (3) 2,997,446 3,088,356 — — 2,725,916 2,991,680 — — Contingent consideration obligations (4) 7,518 10,550 — — — 7,518 10,550 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2023 and 2022, we recorded a (losses) of $(936) and $(16), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2022 are summarized as follows: Contingent Consideration Balance at March 31, 2022 $ 10,550 Adjustments (3,100) Additions 106 Payments (21) Currency translation adjustments (17) Balance at June 30, 2022 $ 7,518

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Jun. 30, 2022
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2022 and 2021 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2022 $ 1,276 $ (211,084) $ (209,808) Other Comprehensive (Loss) Income before reclassifications 154 (178,594) (178,440) Amounts reclassified from Accumulated Other Comprehensive (Loss) Income (125) — (125) Net current-period Other Comprehensive (Loss) Income 29 (178,594) (178,565) Balance at June 30, 2022 $ 1,305 $ (389,678) $ (388,373) (1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2021 $ (5,519) $ (55,724) $ (61,243) Other Comprehensive Income (Loss) before reclassifications 591 24,933 25,524 Amounts reclassified from Accumulated Other Comprehensive (Loss) (1,098) — (1,098) Net current-period Other Comprehensive (Loss) (507) 24,933 24,426 Balance at June 30, 2021 $ (6,026) $ (30,791) $ (36,817) (1) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Assets	$ 11,188,006		$ 11,423,594
Deferred Revenue, Revenue Recognized	57,528	$ 35,722
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,419,128	$ 6,585,015	6,544,637	$ 3,891,468
Liabilities	4,768,878		4,878,957
Accounts Receivable, after Allowance for Credit Loss, Current	763,788		799,041
Inventory, Net	620,404		574,999
Other Prepaid Expense, Current	147,428		156,637
Accrued Liabilities, Current	317,643		306,544
Retained Earnings (Accumulated Deficit)	2,057,175		$ 1,999,244
Revenue, Remaining Performance Obligation, Amount	$ 1,574,000
Expected recognition within the next year [Member]
Revenue, Remaining Performance Obligation, Percentage	62%
Expected recognition beyond the next year [Member] [Member]
Revenue, Remaining Performance Obligation, Percentage	31%

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022		Jun. 30, 2021	Mar. 31, 2022
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs	[1]	$ 9,832		$ 140,996
Cantel Acquisition Assumed Debt Obligations		721,284
Operating Lease, Right-of-Use Asset		182,357			$ 188,480
Goodwill		4,321,176			4,404,343
Payments to Acquire Businesses, Net of Cash Acquired		0		547,353
Equity Securities, FV-NI, Gain (Loss)		(936)		(16)
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Cash		0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Accounts Receivable		0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory		0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment		(1,282)
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Lease right-of-use assets, net		0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Asset		0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles		0
Goodwill, Purchase Accounting Adjustments		22,088
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Assets		20,806
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Convertible debt, par value		0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Current Liabilities		5,595
Business Combination Provisional Information Initial Accounting Incomplete ,Adjustment ,Long-term lease obligations		0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Deferred Income Taxes		15,211
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Long-term indebtedness		0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities		20,806
Business Combination, Provisional Information, Initial Accounting Incomplete, Items		0
Cantel Medical Corp.
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs				$ 140,996
Cash		169,073	[2]		169,073
Accounts receivable		172,226	[2]		172,226
Inventory		249,221	[2]		249,221
Property, plant, and equipment		266,078	[2]		267,360
Operating Lease, Right-of-Use Asset		59,720	[2]		59,720
Other assets		72,864	[2]		72,864
Intangible assets		2,942,000	[2]		2,942,000
Goodwill		1,544,469	[2]		1,522,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets		5,475,651	[2]		5,454,845
Current liabilities		253,144	[2]		247,549
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation		47,856	[2]		47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities		685,896	[2]		670,685
Non-current liabilities		721,284	[2]		721,284
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		1,876,180	[2]		1,855,374
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		3,599,471	[2]		3,599,471
Payments to Acquire Businesses, Net of Cash Acquired		3,599,471
Convertible Debt		$ 168,000	[2]		$ 168,000
[1]Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.[2]Net assets acquired

Business Acquisitions and Div_4

Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022		Jun. 30, 2021	Mar. 31, 2022
Business Acquisition [Line Items]
Revenues	$ 1,156,491		$ 968,422
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory	0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment	(1,282)
Operating Lease, Right-of-Use Asset	182,357			$ 188,480
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles	0
Goodwill, Purchase Accounting Adjustments	22,088
Goodwill	4,321,176			4,404,343
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Convertible debt, par value	0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Other Current Liabilities	5,595
Business Combination Provisional Information Initial Accounting Incomplete ,Adjustment ,Long-term lease obligations	0
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Deferred Income Taxes	15,211
Business Combination Provisional Information Initial Accounting Incomplete, Adjustment, Long-term indebtedness	0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities	20,806
Business Combination, Provisional Information, Initial Accounting Incomplete, Items	0
Cantel Medical Corp.
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Cash	169,073	[1]		169,073
Accounts receivable	172,226	[1]		172,226
Inventory	249,221	[1]		249,221
Property, plant, and equipment	266,078	[1]		267,360
Operating Lease, Right-of-Use Asset	59,720	[1]		59,720
Other assets	72,864	[1]		72,864
Intangible assets	2,942,000	[1]		2,942,000
Goodwill	1,544,469	[1]		1,522,381
Total Assets	5,475,651	[1]		5,454,845
Convertible Debt	168,000	[1]		168,000
Current liabilities	253,144	[1]		247,549
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	47,856	[1]		47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	685,896	[1]		670,685
Non-current liabilities	721,284	[1]		721,284
Total Liabilities	1,876,180	[1]		1,855,374
Net Assets	$ 3,599,471	[1]		$ 3,599,471
[1]Net assets acquired

Business Acquisitions and Div_5

Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		$ 1,156,491	$ 968,422
Pre-tax gain or loss on sale of business	[1]	$ 3,878	$ 419
[1]For more information regarding our recent acquisitions and divestitures refer to note 2 titled, "Business Acquisitions and Divestitures" of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022.

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Raw materials	$ 211,453	$ 195,035
Work in process	107,267	76,021
Finished goods	341,109	334,880
Reserve for excess and obsolete inventory	(39,425)	(30,937)
Inventories, net	$ 620,404	$ 574,999

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Land and land improvements	$ 82,795	$ 84,015
Buildings and leasehold improvements	651,071	654,851
Machinery and equipment	899,970	903,649
Information systems	223,455	222,620
Radioisotope	603,761	597,641
Construction in progress	402,795	356,013
Total property, plant, and equipment	2,863,847	2,818,789
Less: accumulated depreciation and depletion	(1,290,510)	(1,266,213)
Property, plant, and equipment, net	$ 1,573,337	$ 1,552,576

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Debt Instrument [Line Items]
Deferred financing costs	$ 24,353	$ 25,278
Term Loan	65,625	177,500
Delayed Draw Term Loan	617,500	625,625
Credit Agreement	92,642	58,908
Total long term debt	2,846,446	2,945,481
Debt, Long-term and Short-term, Combined Amount	2,997,446	3,088,356
Short-term Debt	151,000	142,875
Senior Notes	$ 745,032	$ 758,726
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Delayed draw term loan, current portion	$ 32,500	$ 24,375
Short-term Debt	91,000	91,000
Term loan, current portion	27,500	27,500
Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,350,000	$ 1,350,000

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Accrued payroll and other related liabilities:
Compensation and related items	$ 83,416	$ 71,878
Accrued vacation/paid time off	14,108	13,669
Accrued bonuses	23,174	64,702
Accrued employee commissions	13,598	30,171
Other postretirement benefit obligations-current portion	1,190	1,190
Other employee benefit plans obligations-current portion	2,094	2,111
Total accrued payroll and other related liabilities	137,580	183,721
Accrued expenses and other:
Deferred revenues	100,617	110,791
Service liabilities	47,737	51,365
Self-insured risk reserves-current portion	11,421	8,995
Accrued dealer commissions	34,450	31,700
Accrued warranty	13,443	14,108
Asset retirement obligation-current portion	517	1,181
Accrued interest	18,073	10,014
Other	91,385	78,390
Total accrued expenses and other	317,643	306,544
Other liabilities:
Self-insured risk reserves-long-term portion	19,213	19,213
Other postretirement benefit obligations-long-term portion	7,070	7,335
Defined benefit pension plans obligations-long-term portion	3,601	1,772
Other employee benefit plans obligations-long-term portion	1,183	1,360
Accrued long-term income taxes	12,502	12,225
Asset retirement obligation-long-term portion	11,897	12,362
Long-term liabilities, other	17,609	21,312
Other Liabilities, Noncurrent	$ 73,075	$ 75,579

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	17.90%	24.40%
Uncertain Tax Liability Resulting From IRS Notice	$ 50,000
Income Tax Contingency [Line Items]
Income Tax Examination, Estimate of Possible Loss	12,000
Income tax examination, amount of loss paid	$ 7,500

Contingencies Leases (Details)

Contingencies Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022
Loss Contingencies [Line Items]
Operating Lease, Right-of-Use Asset	$ 182,357	$ 188,480

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022		Jun. 30, 2021	Mar. 31, 2022
Segment Reporting Information [Line Items]
Assets		$ 11,188,006			$ 11,423,594
Revenues		1,156,491		$ 968,422
Segment operating income		158,395		14,324
Restructuring Charges	[1]	26		14
Amortization of acquired intangible assets	[2]	93,929		41,741
Business Combination, Acquisition Related Costs	[3]	9,832		140,996
Impact of TCJA	[4]	173		(49)
(Gain) loss on fair value adjustment of acquisition related contingent consideration		(3,100)		0
Net loss on divestiture of businesses	[2]	3,878		419
Amortization of inventory and property step-up to fair value	[2]	1,637		24,789
Property, Plant and Equipment, Net		1,573,337			1,552,576
Goodwill		4,321,176			4,404,343
Cantel Medical Corp.
Segment Reporting Information [Line Items]
Business Combination, Acquisition Related Costs				140,996
Goodwill		1,544,469	[5]		$ 1,522,381
Healthcare Products
Segment Reporting Information [Line Items]
Revenues		698,526		602,817
Segment operating income		156,497		138,373
Life Sciences
Segment Reporting Information [Line Items]
Revenues		132,207		121,471
Segment operating income		55,305		49,088
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues		220,911		208,902
Segment operating income		109,315		101,927
Corporate
Segment Reporting Information [Line Items]
Segment operating income		(75,943)		(77,273)
Segment operating income
Segment Reporting Information [Line Items]
Revenues		1,156,491		968,422
Segment operating income		264,770		222,234
Dental
Segment Reporting Information [Line Items]
Revenues		104,847		35,232
Segment operating income		$ 19,596		$ 10,119
Dental | Revenue Benchmark | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Percentage		38.60%		35.80%
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues		$ 304,214		$ 267,227
UNITED STATES
Segment Reporting Information [Line Items]
Revenues		834,101		679,250
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues		18,176		21,945
Consumable revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		252,032		206,692
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		59,557		56,536
Sales Revenue, Services, Net [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		267,360		245,235
Sales Revenue, Services, Net [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		32,151		32,190
Capital equipment revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		179,134		150,890
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		$ 40,499		$ 32,745
[1]For more information regarding our restructuring efforts refer to our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022.[2]For more information regarding our recent acquisitions and divestitures refer to note 2 titled, "Business Acquisitions and Divestitures" of our Annual Report on Form 10-K for the year ended March 31, 2022, which was filed with the Securities and Exchange Commission on May 31, 2022.[3]Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.[4] (3) Costs incurred in tax restructuring.

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended
	Jun. 30, 2022 $ / shares shares	Jun. 30, 2021 shares	Jun. 30, 2022 EUR (€) shares	Mar. 31, 2022 $ / shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	100,082,000	90,152,000
Dilutive effect of share equivalents	640,000	840,000
Weighted average shares outstanding and share equivalents - diluted	100,722,000	90,992,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized			50,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001			$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001
Deferred Ordinary Shares			25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	291,000	273,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €			€ 1

Shares and Preferred Shares Pre

Shares and Preferred Shares Preferred Shares (Details)	Jun. 30, 2022 $ / shares
Class of Stock [Line Items]
Preferred shares, par value	$ 0.001

Repurchases of Shares Repurchas

Repurchases of Shares Repurchases of Shares (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jul. 30, 2019	May 07, 2019
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized	$ 294,649		$ 300,000	$ 78,979
Shares repurchased during period, number	68,177
Aggregate value of shares repurchased pursuant to authorization	$ 14,283
Shares obtained in connection with share based compensation award programs	57,704	59,648
Payments for shares obtained in connection with share based compensation programs	$ 11,737	$ 10,670

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	2,812,252
Weighted-average assumptions used for options granted:
Risk-free interest rate	2.41%	1.16%
Expected life of options	5 years 9 months 18 days	5 years 9 months 18 days
Exptected dividend yield of stock	0.80%	0.97%
Expected volatility of stock	24.45%	24.41%
Estimated forfeiture rate	2.54%	2.85%
Summary of share option activity:
Outstanding at March 31, 2017	1,560,954
Granted	222,384
Exercised	(20,640)
Forfeited	(6,326)
Outstanding at June 30, 2017	1,756,372
Exercisable at June 30, 2017	1,109,471
Weighted average exercise price:
Outstanding at March 31, 2017	$ 138.37
Granted	250.06
Exercised	53.20
Forfeited	200.62
Outstanding at June 30, 2017	153.29
Exercisable at June 30, 2017	$ 118.70
Average Remaining Contractual Term, Outstanding at June 30, 2017	6 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding at June 30, 2017	$ 105,081,000
Average Remaining Contractual Term, Exercisable at June 30, 2017	5 years 9 months 18 days
Aggregate Intrinsic Value, Exercisable at June 30, 2017	$ 97,397,000
Non-vested stock options outstanding expected to vest	624,686
Ordinary shares, closing price	$ 206.15
Total intrinsic value of stock options exercised	$ 3,897,000	$ 5,469,000
Net cash proceeds from the exercise of stock options	$ 1,221,000	$ 1,710,000
Weighted average grant date fair value of stock option grants, per share	$ 50.04	$ 36.24
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 88,105,000
Weighted Average Period For Total Compensation Expense Not Yet Recognized	2 years 4 months 24 days
Restricted Stock Units (RSUs)
Weighted average exercise price:
Weighted average grant date fair value of stock option grants, per share	$ 191.18
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	33,677
Number of Restricted Shares, Granted	5,824
Number of Restricted Shares, Vested	(6,218)
Number of Restricted Shares, Canceled	(766)
Number of Restricted Shares, Non-vested at End of Period	32,517
Restricted Stock or Unit Expense	$ 280,402
Share-based Compensation Arrangement by Share-based Payment Award, Conversion Ratio	0.4262
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value Attributable to Pre-Acquisition Services	$ 18,173,000
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value	53,607,000
Share-based Payment Arrangement, Expense	$ 197,000	$ 18,545,000
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	485,510
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 157.37
Number of Restricted Shares, Granted	119,588
Weighted-Average Grant Date Fair Value, Granted	$ 227.46
Number of Restricted Shares, Vested	(137,898)
Weighted-Average Grant Date Fair Value, Vested	$ 121.81
Number of Restricted Shares, Canceled	(6,167)
Weighted-Average Grant Date Fair Value, Canceled	$ 164.04
Number of Restricted Shares, Non-vested at End of Period	461,033
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 155.01
Fair Value, Share-based Payment Awards, Other than Options	$ 17,570,000
RSUs Cantel
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	45,722
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 191.18
Number of Restricted Shares, Vested	(2,578)
Weighted-Average Grant Date Fair Value, Vested	$ 191.18
Number of Restricted Shares, Canceled	(1,318)
Weighted-Average Grant Date Fair Value, Canceled	$ 191.18
Number of Restricted Shares, Non-vested at End of Period	41,826
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 191.18
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 4,438,000

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2022 USD ($)
Product Warranty Liability [Line Items]
Balance, March 31, 2017	$ 14,108
Warranties issued during the period	3,285
Settlement made during the period	(3,950)
Balance, June 30, 2017	$ 13,443

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2022 EUR (€) lb	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)
Prepaid & Other
Derivative [Line Items]
Asset derivatives		$ 1,330	$ 2,780
Liability derivatives		0	0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives		0	0
Liability derivatives		$ 783	$ 198
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb	601,200
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount | €	€ 34,900,000

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (2,349)	$ (1,428)
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (2,824)	$ 664

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt and Equity Securities, Gain (Loss)		$ 936	$ 16
Liabilities:
Contingent consideration obligations		7,518		$ 10,550
Level 1
Assets:
Cash and cash equivalents		316,327		348,320
Equity Securities, FV-NI	[1]	7,178		8,520
Investments		2,140		2,272
Liabilities:
Deferred compensation plans	[1]	1,036		1,240
Long-term Debt, Fair Value	[2]	0		0
Contingent consideration obligations	[3]			0
Foreign Currency Contract, Asset, Fair Value Disclosure	[4]	0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[4]	0		0
Level 2
Assets:
Cash and cash equivalents		0		0
Equity Securities, FV-NI	[1]	0
Investments		0		0
Liabilities:
Deferred compensation plans	[1]	0		0
Long-term Debt, Fair Value	[2]	2,725,916		2,991,680
Contingent consideration obligations	[3]	0		0
Foreign Currency Contract, Asset, Fair Value Disclosure	[4]	1,330		2,780
Foreign Currency Contracts, Liability, Fair Value Disclosure	[4]	783		198
Level 3
Assets:
Cash and cash equivalents		0		0
Investments				0
Liabilities:
Deferred compensation plans	[1]	0		0
Contingent consideration obligations	[3]	7,518		10,550
Foreign Currency Contract, Asset, Fair Value Disclosure	[4]	0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[4]	0		0
Carrying Value
Assets:
Cash and cash equivalents		316,327		348,320
Equity Securities, FV-NI	[1]	7,178		8,520
Investments		2,140		2,272
Liabilities:
Deferred compensation plans	[1]	1,036		1,240
Long-term Debt, Fair Value	[2]	2,997,446		3,088,356
Contingent consideration obligations	[3]	7,518		10,550
Foreign Currency Contract, Asset, Fair Value Disclosure	[4]	1,330		2,780
Foreign Currency Contracts, Liability, Fair Value Disclosure	[4]	$ 783		$ 198
[1]We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2023 and 2022, we recorded a (losses) of $(936) and $(16), respectively, related to these investments.[2] We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Mar. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration		$ 7,518	$ 10,550
Additions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		106
Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(21)
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(17)
Adjustments to Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(3,100)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	[1]	$ 7,518	10,550
Fair value			$ 0
[1]Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Fair Value Measurements Availab

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Debt Securities, Available-for-sale [Line Items]
Equity Securities, FV-NI, Gain (Loss)	$ (936)	$ (16)

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022		Jun. 30, 2021		Mar. 31, 2022		Mar. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (388,373)		$ (36,817)		$ (209,808)		$ (61,243)
Other Comprehensive Income (Loss), Net of Tax	(178,440)		25,524
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	125		1,098
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	178,565		(24,426)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(1,305)	[1]	6,026	[2]	(1,276)	[1]	5,519	[2]
Other Comprehensive Income (Loss), Net of Tax	(154)	[1]	(591)	[2]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	125	[1]	1,098	[2]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	(29)	[1]	507	[2]
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	(389,678)	[3]	(30,791)	[4]	$ (211,084)	[3]	$ (55,724)	[4]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(178,594)	[3]	24,933	[4]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	[3]	0	[4]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	$ 178,594	[3]	$ (24,933)	[4]
[1]The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.[2]Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.[3]The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.[4]The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Uncategorized Items - ste-20220

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 348,320,000
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 220,531,000